MaaT Pharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.11.24	MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS) (Businesswire)
07.11.24	MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD (Businesswire)
05.11.24	MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes (Businesswire)
15.10.24	MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease (Businesswire)
19.09.24	MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update (Businesswire)
04.09.24	MaaT Pharma To Present and Participate in Investor and Medical Conferences in September (Businesswire)
02.07.24	MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT (Businesswire)
25.06.24	MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16 (Businesswire)
24.06.24	MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer (Businesswire)
15.05.24	MaaT Pharma announces the successful completion of its Global Offering of 19.2 Million Euros (Businesswire)
14.05.24	MaaT Pharma Launches a Global Offering of approximately 18 Million Euros (Businesswire)
07.05.24	MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024 (Businesswire)
15.04.24	MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event (Businesswire)
28.03.24	MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview (Businesswire)
12.03.24	MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference (Businesswire)
29.02.24	MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) (Businesswire)
12.12.23	MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations (Businesswire)
11.12.23	MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023 (Businesswire)
30.11.23	MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan (Businesswire)
09.11.23	MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results (Businesswire)
06.11.23	MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT (Businesswire)
02.11.23	MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference (Businesswire)
31.10.23	MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies (Businesswire)
26.10.23	MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013 (Businesswire)
26.09.23	MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update (Businesswire)
12.09.23	MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies (Businesswire)
07.09.23	MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation aiming to improve overall survival in patients undergoing Hematopoietic Stem Cell transplantation (Businesswire)
27.07.23	MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results (Businesswire)
26.07.23	MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in aGvHD (Businesswire)
20.07.23	MaaT Pharma Joins Microbiome Therapeutics Innovation Group (Businesswire)
21.06.23	MaaT Pharma Announces New Appointments to the Board and Executive Team (Businesswire)
09.05.23	MaaT Pharma Announces Cash and Revenues for the First Quarter of 2023 (Businesswire)
24.04.23	MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease (Businesswire)
11.04.23	MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at 49th EBMT Annual Meeting (Businesswire)
30.03.23	MaaT Pharma Announces 2022 Annual Results and Provides a Business Overview (Businesswire)
27.03.23	MaaT Pharma Receives Two Clinical Trial Application Authorizations to Evaluate MaaT033 in Two Therapeutic Indications in Europe (Businesswire)
17.02.23	MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders (Businesswire)
27.01.23	MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux (Businesswire)
24.01.23	MaaT Pharma Provides Corporate Update and Highlights Key Expected Milestones in 2023 (Businesswire)
11.12.22	MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting (Businesswire)
10.12.22	MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting (Businesswire)
29.11.22	MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference (Businesswire)
08.11.22	MaaT Pharma Reports Cash and Revenues for Third Quarter 2022 (Businesswire)
07.11.22	MaaT Pharma Announces Participation in Scientific and Investor Conferences in November (Businesswire)
03.11.22	MaaT Pharma Announces Oral and Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting (Businesswire)
04.10.22	MaaT Pharma Appoints Nathalie Corvaïa as Chief Scientific Officer and Strengthens its R&D Activities in Immuno-Oncology (Businesswire)
29.09.22	MaaT Pharma Publishes its Half Year Results and Provides a Business Overview (Businesswire)
08.09.22	MaaT Pharma Announces Participation in Three Upcoming Investor Conferences in September (Businesswire)
28.07.22	MaaT Pharma Reports Cash and Revenues for Second Quarter 2022 (Businesswire)
02.06.22	MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.14	1.54 %	K V
UBS Group	28.08	1.48 %	K V
Swiss Re	130.05	1.05 %	K V
Part Grp Hldg	1’266.00	0.96 %	K V
ABB	49.48	0.94 %	K V
Geberit	525.20	0.27 %	K V
Alcon	78.04	0.05 %	K V
Givaudan	3’868.00	-0.31 %	K V
CieFinRichemont	121.20	-0.57 %	K V
Sonova Hldg	301.00	-0.99 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu MaaT Pharma

Aktien Top/Flop

Meistgelesene Nachrichten